B6E Stock Chart & Stats
€36.06
-€0.20(-0.72%)
At close: 4:00 PM EST
€36.06
-€0.20(-0.72%)
Day’s Range― - ―
52-Week Range€23.62 - €43.62
Previous CloseN/A
Volume0.00
Average Volume (3M)45.00
Market Cap
€14.43B
Enterprise Value€178.24K
Total Cash (Recent Filing)€1.08B
Total Debt (Recent Filing)€17.59B
Price to Earnings (P/E)174.7
Beta1.03
Next Earnings
Oct 27, 2026EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.97
Shares Outstanding357,412,840
10 Day Avg. Volume55
30 Day Avg. Volume45
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)3.04
Price to Sales (P/S)4.06
P/FCF Ratio13.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€45.93Price Target Upside27.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)1.7
Revenue Forecast (FY)€2.96B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthSobi’s growing TTM free cash flow and strong operating cash generation provide durable financial flexibility to fund R&D, support launches, and pursue partnerships without relying solely on external financing. High FCF relative to net income also supports earnings quality and balance-sheet resilience over months.
Sound Balance SheetA sizable equity base and moderate leverage give Sobi the capacity to absorb shocks and finance strategic initiatives. This structural balance-sheet strength supports long-term investment in the rare-disease portfolio and underwriting of commercial expansion in multiple markets without immediate liquidity stress.
Consistent Revenue Growth & Operating StrengthSteady mid-single-digit revenue growth and a robust TTM EBITDA margin indicate enduring commercial traction in rare-disease niches. Persistent top-line growth and healthy operating margins imply durable product demand, pricing power in specialty markets, and a sound platform for future launches and partnership income.
Bears Say
Compressed Net ProfitabilityNet income has fallen materially from prior peaks, creating a large gap between EBITDA and reported profit. Below-the-line or non-operating pressures have compressed net margins, increasing earnings volatility and reducing retained earnings available for reinvestment or to improve returns on equity over the medium term.
Rising Leverage Vs Prior YearLeverage increasing versus the prior year raises structural financial risk: higher debt levels can limit strategic flexibility, elevate interest expense sensitivity, and constrain capacity for opportunistic M&A or incremental R&D should profitability remain subdued over the coming quarters.
Variable Cash ConversionCash conversion has shown variability, including a negative FCF year in 2023, so current strong FCF may not be fully persistent. Irregular conversion of EBITDA to free cash reduces predictability for funding pipelines, dividends, or buybacks and raises downside risk if revenue or working-capital dynamics reverse.
B6E FAQ
What was Swedish Orphan Biovitrum AB’s price range in the past 12 months?
Swedish Orphan Biovitrum AB lowest stock price was €23.62 and its highest was €43.62 in the past 12 months.
What is Swedish Orphan Biovitrum AB’s market cap?
Swedish Orphan Biovitrum AB’s market cap is €14.43B.
When is Swedish Orphan Biovitrum AB’s upcoming earnings report date?
Swedish Orphan Biovitrum AB’s upcoming earnings report date is Oct 27, 2026 which is in 97 days.
How were Swedish Orphan Biovitrum AB’s earnings last quarter?
Swedish Orphan Biovitrum AB released its earnings results on Jul 16, 2026. The company reported €0.284 earnings per share for the quarter, missing the consensus estimate of €0.308 by -€0.023.
Is Swedish Orphan Biovitrum AB overvalued?
According to Wall Street analysts Swedish Orphan Biovitrum AB’s price is currently Undervalued.
Does Swedish Orphan Biovitrum AB pay dividends?
Swedish Orphan Biovitrum AB does not currently pay dividends.
What is Swedish Orphan Biovitrum AB’s EPS estimate?
Swedish Orphan Biovitrum AB’s EPS estimate is 0.57.
How many shares outstanding does Swedish Orphan Biovitrum AB have?
Swedish Orphan Biovitrum AB has 357,412,840 shares outstanding.
What happened to Swedish Orphan Biovitrum AB’s price movement after its last earnings report?
Swedish Orphan Biovitrum AB reported an EPS of €0.284 in its last earnings report, missing expectations of €0.308. Following the earnings report the stock price went up 4.339%.
Which hedge fund is a major shareholder of Swedish Orphan Biovitrum AB?
Currently, no hedge funds are holding shares in DE:B6E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
B6E Stock 12 Month Forecast
Average Price Target
€45.93
▲(27.38% Upside)
Technical Analysis
Orexo AB
―
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enorama Pharma AB
―